Read time: 1 min
Researchers from La Jolla Institute for Allergy and Immunology (CA, USA) have identified a subset of T cells whose frequency could serve as an early childhood signature to predict the risk of developing asthma.
Read time: 1 min
An author’s perspective: Ragu Ramanathan on an LC–MS/HRMS assay for quantifying coproporphyrins as organic anion-transporting polypeptide biomarkers
We talk to Ragu Ramanathan about his work on LC–MS/HRMS assay for quantifying coproporphyrins as organic anion-transporting peptide biomarkers
A highly selective and sensitive LC–MS/HRMS assay for quantifying coproporphyrins as organic anion-transporting peptide biomarkers
Find out more about highly selective and sensitive LC–MS/HRMS assay for quantifying coproporphyrins as organic anion-transporting peptide biomarkers in this article published in Bioanalysis.
Bioanalysis Zone and Bioanalysis welcome unsolicited submissions to both the journal and website!
From novel analytical instrumentation to the recent developments in the bioanalysis of biopharmaceuticals and biomarkers, as the New Year starts we’re looking back on the bioanalytical highlights from 2017.
A Swedish research team has identified a method of drug and disease detection through the analysis of various compounds in exhaled breath.
We interviewed Shalini Prasad and Sriram Muthukumar about their new technology, termed EnLiSense LLC, that specializes in sensor technologies for enhancing lifestyle decisions.
At Reid 2017 we interviewed Jennifer Hincks, Principal Scientist at LGC, about her role in setting up a new flow cytometry service. Jennifer discusses her passion for flow cytometry, how it can be used to analyze biomarkers and how this field can be regulated and standardized.
At Reid 2017 we interviewed James Rudge, Global Microsampling Specialist at Neoteryx, about his role in developing volumetric absorptive microsampling. James talks about his interest in biomarkers, what technologies he uses to analyze biomarkers and how he thinks the ‘omics’ field will come online.
Neil Henderson discusses his experiences with oligonucleotides, the technologies that he uses and his work as part of the Translational Biomarker and Bioanalysis group at Astrazeneca.